Catalyst Pharmaceuticals, INC Form 4 insider transactions

Catalyst Pharmaceuticals Director David S. Tierney converted 1,413 restricted stock units into common stock on December 8, 2025, as part of a scheduled vesting.

Catalyst Pharmaceuticals Director Tamar Thompson acquired 1,413 shares of common stock following the vesting of restricted stock units.

Catalyst Pharmaceuticals' Chief Commercial Officer, Jeffrey Del Carmen, reported the vesting of 8,039 restricted stock units and subsequent share transactions.

Molly Harper, a Director at Catalyst Pharmaceuticals, Inc., acquired 1,413 shares of common stock through the vesting of restricted stock units.

Patrick J. McEnany, Chairman of Catalyst Pharmaceuticals, acquired 3,534 shares of common stock through the vesting of restricted stock units.

Catalyst Pharmaceuticals Director Donald A. Denkhaus converted 1,413 restricted stock units into common stock on December 8, 2025, increasing his direct holdings.

Catalyst Pharmaceuticals' Chief Strategy Officer, Preethi Sundaram, reported the vesting of restricted stock units and subsequent tax-related share withholding.

Patrick J. McEnany, Chairman of Catalyst Pharmaceuticals, Inc., gifted 135,000 shares of common stock to irrevocable family trusts.

Catalyst Pharmaceuticals' Chief Commercial Officer, Jeffrey Del Carmen, exercised options and subsequently sold 10,983 shares of common stock for personal reasons.

Catalyst Pharmaceuticals' Chief Strategy Officer, Preethi Sundaram, reported recent stock option grants, RSU vestings, and share disposals for tax purposes.

Catalyst Pharmaceuticals' Chief Operating & Scientific Officer, Steve Miller, reported the acquisition of common stock and new equity awards, increasing his beneficial ownership.

Catalyst Pharmaceuticals' Chief HR Officer, Gregg Russo, acquired 20,531 stock options and 6,197 Restricted Stock Units, aligning interests with shareholders.

Catalyst Pharmaceuticals Director Tamar Thompson reported significant equity awards, including new options and restricted stock units, alongside the vesting of existing RSUs.

Catalyst Pharmaceuticals' Executive Vice President and CFO, Michael Wayne Kalb, reported significant changes in his beneficial ownership of company stock, including new option and RSU grants and the vesting of existing units.

Catalyst Pharmaceuticals Director David S. Tierney reported new equity awards and the vesting of restricted stock units, increasing his beneficial ownership.

Catalyst Pharmaceuticals Chairman Patrick J. McEnany acquired common stock and received new equity awards, increasing his beneficial ownership.

Catalyst Pharmaceuticals Director Molly Harper reported the acquisition of stock options and restricted stock units, alongside the vesting and delivery of a tranche of RSUs.

Catalyst Pharmaceuticals CEO Richard J. Daly reported new equity grants and RSU vesting, alongside shares withheld for taxes.

Catalyst Pharmaceuticals Director Donald A. Denkhaus reported the grant of new stock options and restricted stock units, alongside the conversion of existing RSUs into common stock.

Catalyst Pharmaceuticals' Chief Compliance/Legal Officer, Brian Elsbernd, reported recent acquisitions of common stock, options, and restricted stock units, alongside tax-related share disposals.

Catalyst Pharmaceuticals' Chief Commercial Officer, Jeffrey Del Carmen, reported the acquisition of new stock options and restricted stock units, alongside the vesting and tax-related disposition of existing units.

Catalyst Pharma Director Daniel J. Curran acquired 18,115 options and 5,468 RSUs.

Catalyst Pharmaceuticals' Chief Medical Officer, William T. Andrews, received new equity awards including stock options and restricted stock units.

Catalyst Pharmaceuticals' Chief Compliance/Legal Officer, Brian Elsbernd, sold 40,000 shares of common stock for approximately $22.7 per share.

Catalyst Pharmaceuticals' Chief Compliance/Legal Officer, Brian Elsbernd, exercised stock options and subsequently sold a portion of the acquired shares to cover costs.

Catalyst Pharmaceuticals' Chief Compliance/Legal Officer, Brian Elsbernd, exercised stock options and subsequently sold a total of 50,000 common shares for personal reasons.

A director at Catalyst Pharmaceuticals, David S. Tierney, exercised stock options and subsequently sold a portion of the acquired shares to cover costs and taxes.

Catalyst Pharmaceuticals' Chief Operating and Scientific Officer, Steve Miller, exercised stock options and subsequently sold common stock to cover costs and taxes.

Catalyst Pharmaceuticals CEO Richard J. Daly exercised 50,000 stock options and subsequently sold 22,970 shares to cover the exercise price and tax obligations.

Preethi Sundaram, Chief Strategy Officer of Catalyst Pharmaceuticals, Inc. (CPRX), reported the sale of 3,924 shares of common stock for personal reasons in early June 2025.